NCT00002835 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00002835/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
Ifosfamide [clinicaltrials_resource:198e1aa60ec2b39d48ea5da7b4c38ea1]Carmustine [clinicaltrials_resource:5507519ebb51f02d4398dbc81898b8c4]Etoposide (VP-16) [clinicaltrials_resource:7684137398f92ce69f13de782b2c74b4]Peripheral Blood Stem Cell Transplantation [clinicaltrials_resource:7eb39008a027fe5facdddb94a03acf98]Melphalan [clinicaltrials_resource:92909b69a5bcdcb4eff3a7324d178cd9]Cytarabine (ARA-C) [clinicaltrials_resource:cd579607a1b44be37f0f21a8921bb0cc]Filgrastim (G-CSF) [clinicaltrials_resource:cdc2bbe64f1dfe7cdf6fc7ba7219e83a]mitoxantrone hydrochloride (DHAD) [clinicaltrials_resource:d01c9aba9ec8b8d83b19971d10c4bdf7]clinicaltrials:NCT00002835
arm group [clinicaltrials_vocabulary:arm-group]
NCT00002835 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00002835/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
Bio2RDF identifier
NCT00002835/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a4df479e15ec87e5cf6d58e58b6e85
description [clinicaltrials_vocabulary:description]
3 courses of early intensifica ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:NCT00002835/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
title
NCT00002835 arm group 08a4df479e15ec87e5cf6d58e58b6e85
@en
type
label
NCT00002835 arm group 08a4df47 ...... 4df479e15ec87e5cf6d58e58b6e85]
@en